AhlulBayt News Agency: Researchers at an Iranian technology company have succeeded in obtaining the instructions for the production of a radioactive medicine for lymph node cancer, which provides doctors with accurate diagnosis of the disease.
Researchers at one of the Iranian technology companies have obtained the formula for the production of the active ingredient of the radioactive medicine Technetium-99, which provides accurate diagnosis of lymph node cancer.
Previously, the monopoly on the production of this radioactive medicine was only in the hands of the United States.
Iranian researchers announced that this achievement can improve the quality of life for people with the disease.
Technetium-99 radioactive medicine is a very expensive product, and its production technology was only in the hands of an American company, but now its technology has been localized in Iran, and it is expected to enter the market officially in a year and a half.
The size of the particles of this product is less than 10 nanometers, and it has the ability to move in the lymphatic system. This product is converted into a kit at the Atomic Energy Organization of the Islamic Republic of Iran and then labeled with Technetium-99 radioisotope at nuclear medicine centers a few minutes before it is injected into the patient.
It is then injected directly (into the tumor) or subcutaneously (in the lymphatic area) into the patient.
This active ingredient begins to move in the lymphatic system, and areas with receptors of cancer cells are identified in scan images, and surgeons can identify and selectively remove lymph nodes involved in tumors and cancer cells.
Currently, most surgeons remove a significant part of the lymphatic system along with the main tumor during surgery to prevent the spread of cancer, which has irreparable consequences for the patient. However, with the production of this product, these complications will no longer affect patients.
/129
Researchers at one of the Iranian technology companies have obtained the formula for the production of the active ingredient of the radioactive medicine Technetium-99, which provides accurate diagnosis of lymph node cancer.
Previously, the monopoly on the production of this radioactive medicine was only in the hands of the United States.
Iranian researchers announced that this achievement can improve the quality of life for people with the disease.
Technetium-99 radioactive medicine is a very expensive product, and its production technology was only in the hands of an American company, but now its technology has been localized in Iran, and it is expected to enter the market officially in a year and a half.
The size of the particles of this product is less than 10 nanometers, and it has the ability to move in the lymphatic system. This product is converted into a kit at the Atomic Energy Organization of the Islamic Republic of Iran and then labeled with Technetium-99 radioisotope at nuclear medicine centers a few minutes before it is injected into the patient.
It is then injected directly (into the tumor) or subcutaneously (in the lymphatic area) into the patient.
This active ingredient begins to move in the lymphatic system, and areas with receptors of cancer cells are identified in scan images, and surgeons can identify and selectively remove lymph nodes involved in tumors and cancer cells.
Currently, most surgeons remove a significant part of the lymphatic system along with the main tumor during surgery to prevent the spread of cancer, which has irreparable consequences for the patient. However, with the production of this product, these complications will no longer affect patients.
/129